SIMS CAP — DHIS2 Table 2.2 — ICAP Tanzania

ICAP Tanzania / SIMS CAP · DHIS2 Table 2.2

Updated 28 Oct 2026

Region

Council

Site

Year

Month

Date from

Date to

Supervisory visits

256

DHIS2 Table 2.2 log rows

Sites visited

89

Unique facilities (HFR)

CAP reports

112

With DHIS2 Table 2.2 data

Regions

2

In visit log

Sites visited over time

Unique facilities with ≥1 supervisory visit per last 4 weeks

Latest period (sites) 0

Peak period (sites) 62

Visit events in range 256

180 Total

in the 31 (17.2%)
clients were 19 (10.6%)
eligible for 19 (10.6%)
VL results 18 (10.0%)
follow up 18 (10.0%)
Other phrases 75 (41.7%)

View full breakdown →

25 supervisory visits 24 facilities

59 — Virally suppressed, of those with a documented VL result

25 supervisory visits 22 facilities

60 — Missed appointments traced and returned before interruption

19 supervisory visits 19 facilities

66 — Newly enrolled on PrEP (PrEP_NEW)

18 supervisory visits 17 facilities

58 — Infants tested by early infant diagnosis

18 supervisory visits 18 facilities

68 — HIV-exposed infants with final status known by 18 months

17 supervisory visits 16 facilities

56 — People tested for HIV (HTS_TST)

15 supervisory visits 14 facilities

57 — People testing HIV positive (HTS_POS)

14 supervisory visits 12 facilities

50 — People on ART (TX_CURR)

8 supervisory visits 8 facilities

62 — Contacts elicited per index client

7 supervisory visits 6 facilities

61 — Returned after interruption (missed 28–90 days)

5 supervisory visits 5 facilities

67 — Screen-positive women treated (cryotherapy, thermocoagulation or LEEP)

5 supervisory visits 5 facilities

Unspecified DoS milestone

4 supervisory visits 4 facilities

63 — Contacts elicited who are tested

4 supervisory visits 3 facilities

65 — Index testing positivity, with linkage to treatment

4 supervisory visits 4 facilities

74 - Stock availability at the facility

3 supervisory visits 3 facilities

53 — New HIV diagnoses, children and adults

3 supervisory visits 3 facilities

ICT & SI Technical Support and Mentorship

3 supervisory visits 3 facilities

Laboratory System

2 supervisory visits 1 facility

54 — New HIV diagnoses among infants (0–12 months)

2 supervisory visits 2 facilities

64 — Patients on ART who experience treatment interruption

2 supervisory visits 2 facilities

75 - Facilities submitting stock reports

2 supervisory visits 2 facilities

[>90%] of laboratory-based testing sites participating and pass Proficiency testing (PT) in Mwanza

2 supervisory visits 2 facilities

HIV/TB Diagnostics and AHD

2 supervisory visits 2 facilities

VL Coverage

2 supervisory visits 2 facilities

Viral Load Coverage

1 supervisory visit 1 facility

1.3 Build capacity of CHWs, peer educators, and local government for community demand generation and follow-up

1 supervisory visit 1 facility

29 and 51_ Data reporting and LIS Utilization

1 supervisory visit 1 facility

50, 51 and 53_Laboratory Supplies and Quality Management

1 supervisory visit 1 facility

50,51 and 53-Laboratory Equipment and Supplies

1 supervisory visit 1 facility

55 — Pregnant women living with HIV who received ART

1 supervisory visit 1 facility

69 — HIV-positive pregnant women virally suppressed at delivery

1 supervisory visit 1 facility

74 - Facilities Submitting stock reports

1 supervisory visit 1 facility

74 - Facilities submitting stock reports

1 supervisory visit 1 facility

75 - Facility submitting stock reports

1 supervisory visit 1 facility

75 - Stock availability at the facility

1 supervisory visit 1 facility

75 - Stock availability at the facilities

1 supervisory visit 1 facility

75 - facilities submitting stock reports

1 supervisory visit 1 facility

Biometric Rescanned ART clients

1 supervisory visit 1 facility

EAC Cascade

1 supervisory visit 1 facility

UCS Implementation

1 supervisory visit 1 facility

Tb Presumptive not tested

1 supervisory visit 1 facility

TB-prevention therapy.

1 supervisory visit 1 facility

ICT Technical Support

1 supervisory visit 1 facility

Improve molecular testing turnaround time (TAT) to ensure at least 85% of molecular test results, including HVL, DBS, and TB, are returned within 10 days.

1 supervisory visit 1 facility

BRA Rescanning Follow up

1 supervisory visit 1 facility

Biometric Registration

1 supervisory visit 1 facility

Biometric Rescanning

1 supervisory visit 1 facility

Enhancing Adherence Counselling

1 supervisory visit 1 facility

Viral load testing

1 supervisory visit 1 facility

TB-ART

1 supervisory visit 1 facility

PMD module not update since July 2026 to date

1 supervisory visit 1 facility

Improving molecular testing turnaround time (TAT) to ensure at least 85% of molecular test results, including HVL, DBS, and TB, are returned within 10 days.

1 supervisory visit 1 facility

Under reporting of GBV data July to Sept 2026 report

1 supervisory visit 1 facility

TB/HIV data discripancy

1 supervisory visit 1 facility

Martenal Re testing

1 supervisory visit 1 facility

BF 3

1 supervisory visit 1 facility

Cecap call back compaign

1 supervisory visit 1 facility

TB/HIV cascade and TPT cascade

1 supervisory visit 1 facility

Advanced HIV Disease (AHD) and TB Testing Services

1 supervisory visit 1 facility

Need New Computer for CTC department

1 supervisory visit 1 facility

Computer and Systems maintenance and IT assessment need for the new financial year.

1 supervisory visit 1 facility

Transition of PALD

1 supervisory visit 1 facility

TO verification of 15 clients who transfered out the region

1 supervisory visit 1 facility

TX NEW offering of AHD service and Elcm session

1 supervisory visit 1 facility

TB and Advanced HIV Disease (AHD) Results Documentation

1 supervisory visit 1 facility

Laboratory Equipment and Supplies

1 supervisory visit 1 facility

HPV Vaccination

1 supervisory visit 1 facility

Software and hardware maintenance.

1 supervisory visit 1 facility

TB screening and treatment cascade

1 supervisory visit 1 facility

Biometric rescanning and electronic module in CTC2 database misbehave.